612 related articles for article (PubMed ID: 26386501)
1. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
Macdonald PS
Clin Ther; 2015 Oct; 37(10):2199-205. PubMed ID: 26386501
[TBL] [Abstract][Full Text] [Related]
2. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau J; Shi VC; Solomon SD; Swedberg K; Zile MR;
Eur J Heart Fail; 2013 Sep; 15(9):1062-73. PubMed ID: 23563576
[TBL] [Abstract][Full Text] [Related]
3. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
4. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
McMurray JJ
Eur J Heart Fail; 2015 Mar; 17(3):242-7. PubMed ID: 25756942
[TBL] [Abstract][Full Text] [Related]
5. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
6. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile MR;
N Engl J Med; 2014 Sep; 371(11):993-1004. PubMed ID: 25176015
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
Gori M; Volterrani M; Piepoli M; Senni M
Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659
[TBL] [Abstract][Full Text] [Related]
9. Neprilysin Inhibitors in Cardiovascular Disease.
Kang G; Banerjee D
Curr Cardiol Rep; 2017 Feb; 19(2):16. PubMed ID: 28185171
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings.
Książczyk M; Lelonek M
Heart Fail Rev; 2020 May; 25(3):393-402. PubMed ID: 31713710
[TBL] [Abstract][Full Text] [Related]
11. LCZ696 : a new paradigm for the treatment of heart failure?
Minguet J; Sutton G; Ferrero C; Gomez T; Bramlage P
Expert Opin Pharmacother; 2015 Feb; 16(3):435-46. PubMed ID: 25597387
[TBL] [Abstract][Full Text] [Related]
12. LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?
Pham AQ; Patel Y; Gallagher B
J Pharm Pract; 2015 Apr; 28(2):137-45. PubMed ID: 25864789
[TBL] [Abstract][Full Text] [Related]
13. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
Desai AS; Solomon S; Claggett B; McMurray JJ; Rouleau J; Swedberg K; Zile M; Lefkowitz M; Shi V; Packer M
Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296397
[TBL] [Abstract][Full Text] [Related]
14. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
Desai AS; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Chen F; Gong J; Rizkala AR; Brahimi A; Claggett B; Finn PV; Hartley LH; Liu J; Lefkowitz M; Shi V; Zile MR; Solomon SD
Eur Heart J; 2015 Aug; 36(30):1990-7. PubMed ID: 26022006
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact.
Buggey J; Mentz RJ; DeVore AD; Velazquez EJ
J Card Fail; 2015 Sep; 21(9):741-50. PubMed ID: 26209000
[TBL] [Abstract][Full Text] [Related]
16. Sacubitril/valsartan (LCZ696) for the treatment of heart failure.
Gori M; Senni M
Expert Rev Cardiovasc Ther; 2016; 14(2):145-53. PubMed ID: 26642078
[TBL] [Abstract][Full Text] [Related]
17. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
18. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.
Braunwald E
J Am Coll Cardiol; 2015 Mar; 65(10):1029-41. PubMed ID: 25766951
[TBL] [Abstract][Full Text] [Related]
19. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
Jhund PS; McMurray JJ
Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Packer M; McMurray JJ; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile M; Andersen K; Arango JL; Arnold JM; Bělohlávek J; Böhm M; Boytsov S; Burgess LJ; Cabrera W; Calvo C; Chen CH; Dukat A; Duarte YC; Erglis A; Fu M; Gomez E; Gonzàlez-Medina A; Hagège AA; Huang J; Katova T; Kiatchoosakun S; Kim KS; Kozan Ö; Llamas EB; Martinez F; Merkely B; Mendoza I; Mosterd A; Negrusz-Kawecka M; Peuhkurinen K; Ramires FJ; Refsgaard J; Rosenthal A; Senni M; Sibulo AS; Silva-Cardoso J; Squire IB; Starling RC; Teerlink JR; Vanhaecke J; Vinereanu D; Wong RC;
Circulation; 2015 Jan; 131(1):54-61. PubMed ID: 25403646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]